U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Diso... (cts with a focus on pharmaceutical produ...)

HOME >> BIOLOGY >> TECHNOLOGY

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

Date:11/20/2007

cts, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. The Otsuka Pharmaceutical Group comprises 99 companies and employs approximately 31,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned U.S. $7.2 billion in annual revenues in fiscal 2006.

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

For more information and FULL PRESCRIBING INFORMATION,

including Boxed WARNING, visit: http://www.abilify.com

Visit Bristol-Myers Squibb at: http://www.bms.com

Visit Otsuka Pharmaceutical Co., Ltd. at: http://www.otsuka-global.com

* Inadequate response for prospective treatment was defined as less than

50 percent improvement on the 17-item version of the Hamilton Depression

Rating Scale (HAMD17), minimal HAMD17 score of 14, and a Clinical Global

Impressions Improvement rating of no better than minimal improvement.

References

(1) Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer-Term

Outcomes in Depressed Outpatients Requiring One or Several Treatment

Steps: A STAR*D Report. Am J Psych. 2006;163:1905-1917.

(2) Kessler RC, Berglund P, Demler O, et al. The epidemiology of major

depressive disorder: results from the national comorbidity survey

replication (NCS-R). JAMA. June 18 2003;289(23):3095-3105.

(3)
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)

Post Your Comments:

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Diso...(cts with a focus on pharmaceutical produ...)